Tag: life sciences
-
BioNTech to Provide Personal Cancer Immunotherapies in UK
The biotechnology company BioNTech SE is partnering with the U.K. government to provide up to 10,000 personalized cancer immunotherapy treatments by 2030.
-
Biotech Alliance Creating Circular RNA Cancer Drug
A partnership of biotechnology components and therapy companies aims to develop new drugs made from circular forms of RNA, starting with a colorectal cancer treatment.
-
Protein Chemistry Biotech Gains Collaboration, Venture Funds
An enterprise discovering new drugs with optical light-based protein chemistry is emerging from stealth, including work with biopharmaceutical company Genentech.
-
Trial Shows Anti-Inflammatory Drug Stops Covid-19 Hospitalization
Findings from a clinical trial show an anti-inflammatory drug reduces new symptoms among people with Covid-19 infections and keeps them out of the hospital.
-
Company Started for Gene Editing Rare Inherited Diseases
A new enterprise is formed to develop gene-editing therapies for mitochondrial disorders, rare inherited mutations in the energy centers of cells.
-
Implanted Organoid Connects to Brain, Reacts to Visual Cues
Engineers and neuroscientists developed a circuit that in lab mice connects implanted lab-grown brain tissue to the brain’s cognitive center and responds to visual stimuli.
-
Peptide Discovery Company to Gain $3.3B in Licensing Deals
A discoverer of therapeutic peptides signed licensing deals in the past few days with two drug makers that could bring the company as much as $3.3 billion.
-
Infographic – Cancer Start-Up Venture Funds Decline
Funding for new enterprises creating products and services that treat or detect cancer fell more than 40 percent from last year.
-
Food Protein Biotech Adds €4M in Seed Funds
A new company creating protein ingredients for food products from carbon dioxide converted by engineered bacteria is raising €4 million more in seed funds.
-
Cell Biology Tools Companies Merge in $57.8M Deal
Two providers of technologies for cellular analysis are merging to form a new company focusing on cell biology research tools, in a sign of continued industry consolidation.